A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: A double-blind placebo-controlled pilot study

A. Ingber, Y. Cohen, M. Krimsky, Saul Yedgar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Phospholipase A2 hydrolyzes membrane phospholipids releasing arachidonic acid and lysophospholipids. These are key precursors of inflammatory mediators, such as prostaglandins, leukotrienes, thromboxanes and PAF, in numerous inflammatory/allergic diseases, including skin inflammation. Accordingly, inhibition of PLA2 has long been postulated as a potentially potent antiinflammatory therapy. In the present study we tested the effect of a novel PLA2 inhibitor on contact dermatitis in human subjects. A double-blind, placebo-controlled pilot study was conducted on contact dermatitis patients (n = 11) treated with the inhibitor-containing topical preparation (1% cream). Disease severity was assessed by physician's assessment before treatment (day 0) as well as after 14-days and 30-days. Patients treated with 1% PLA2 inhibitor-containing cream showed a 69.9% reduction in disease score while placebo-treated patients showed a reduction of 36.5% with p = 0.0024. The clear improvement in the disease score of inhibitor-treated patients supports the involvement of PLA2 activity in skin inflammation and the therapeutic prospective of its inhibition.

Original languageEnglish
Pages (from-to)191-195
Number of pages5
JournalInternational Journal of Immunopathology and Pharmacology
Volume20
Issue number1
DOIs
StatePublished - 2007

Keywords

  • Contact dermatitis
  • Skin inflammation
  • Topical preparation

Fingerprint

Dive into the research topics of 'A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: A double-blind placebo-controlled pilot study'. Together they form a unique fingerprint.

Cite this